Study Finds Placebo Outperforms LSD Microdosing in Treating Depression
A clinical trial conducted by MindBio Therapeutics found that microdosing LSD did not outperform a placebo in treating major depressive disorder. The results challenge popular claims about the efficacy of microdosing for mental health. The findings may influence ongoing debates regarding alternative therapies for depression.
A new clinical trial suggests that microdosing LSD offers no greater benefit than a placebo in treating major depressive disorder. The study, led by MindBio Therapeutics, an Australian biopharmaceutical company, evaluated 89 adults over eight weeks and used the Montgomery-Åsberg Depression Rating Scale, a standard clinical tool for assessing depression symptoms.
Microdosing, the practice of consuming very small, sub-hallucinogenic doses of psychedelic drugs, has gained popularity in recent years, particularly for its purported mood and focus-enhancing effects. Advocates commonly claim that such practices can help alleviate depression, increase focus, and even boost libido. However, this trial's findings indicate that the positive effects reported by users may largely be the result of the placebo effect.
The findings add to a growing body of evidence questioning the real-world benefits of microdosing psychedelic compounds for mental health conditions. Despite intense public interest and anecdotal support, rigorous scientific evaluation demonstrates the need for caution when considering such therapies as viable treatments for depression.
While studies like this are essential in shaping mental health treatment protocols, the debate over alternative approaches to managing depression—particularly those drawing from the tech and biohacking communities—remains vibrant worldwide.
Source: arstechnica.com
Related Posts
Majority of CEOs Predict Job Losses from AI Within Two Years
A global survey indicates 99% of CEOs expect artificial intelligence to reduce jobs within two years, marking a significant shift in workplace expectations. The findings highlight growing executive confidence in AI technologies and their likely impact on employment.
E.ON Modernises Energy Grid with SAP S/4HANA and AI
E.ON is leveraging SAP S/4HANA to standardise grid data, streamline infrastructure, and enable AI-powered applications such as predictive maintenance and customer automation. The company is focusing on internal technical capabilities, cybersecurity, and embedding digital tools directly into core operations to support reliability and growth in the energy sector.
Walmart Limits Employee AI Use to Manage Rising Costs
Walmart has imposed limits on employee use of its internal AI assistant, Code Puppy, in response to unexpectedly high costs associated with large language model (LLM) usage. The move highlights broader challenges faced by large enterprises as AI billing models shift from flat-rate subscriptions to usage-based pricing.